Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working Party
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Da Jung | - |
dc.contributor.author | Lee, Ho Sup | - |
dc.contributor.author | Moon, Joon-Ho | - |
dc.contributor.author | Sohn, Sang Kyun | - |
dc.contributor.author | Kim, Hyeoung Joon | - |
dc.contributor.author | Cheong, June-Won | - |
dc.contributor.author | Jo, Deog-Yeon | - |
dc.contributor.author | Kim, Hawk | - |
dc.contributor.author | Lee, Hyewon | - |
dc.contributor.author | Bangs, Soo-Mee | - |
dc.contributor.author | Lee, Won Sik | - |
dc.contributor.author | Park, Yong | - |
dc.contributor.author | Lee, Mark Hong | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.contributor.author | Bae, Sung Hwa | - |
dc.contributor.author | Kim, Min Kyoung | - |
dc.date.accessioned | 2021-09-03T00:14:39Z | - |
dc.date.available | 2021-09-03T00:14:39Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2017-10-03 | - |
dc.identifier.issn | 1949-2553 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/81944 | - |
dc.description.abstract | It is often difficult to continue treatment with hypomethylating agent(HMA) in clinical practice because of problems such as toxicities, poor economics, etc. We compared clinical outcomes of those patients who continued HMA and those who discontinued HMA because of other causes, and evaluated factors associated with survival in those patients who discontinued HMA. Patients were divided into two groups: treatment failure, those who stopped treatment due to disease progression; and discontinuation, those who discontinued treatment because of other causes. The median progression free survival(PFS) was 9.2 months (range 7.7 - 10.7 months) vs 28.9 months (range 22.6-35.2) in the treatment failure and discontinuation groups, respectively (P < 0.001). In a multivariate analysis, a lower risk by WPSS was an independent predictive factor for a longer PFS, and a lower risk by WPSS and median number of HMA cycles greater than seven were independent predictive factors for longer overall survival(OS) only in the discontinuation group. Patients who discontinued HMA without disease progression showed a prolonged survival than those who failed HMA treatment. Especially, a lower risk by WPSS and longer duration of HMA treatment may be predictive factors for a longer PFS and OS in patients who discontinued HMA. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | IMPACT JOURNALS LLC | - |
dc.subject | AZACITIDINE TREATMENT FAILURE | - |
dc.subject | LEUKEMIA GROUP-B | - |
dc.subject | ELDERLY-PATIENTS | - |
dc.subject | PHASE-III | - |
dc.subject | LOW-RISK | - |
dc.subject | DECITABINE | - |
dc.subject | THERAPY | - |
dc.subject | CANCER | - |
dc.subject | CARE | - |
dc.subject | ORGANIZATION | - |
dc.title | Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working Party | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Yong | - |
dc.identifier.doi | 10.18632/oncotarget.18258 | - |
dc.identifier.wosid | 000412111300104 | - |
dc.identifier.bibliographicCitation | ONCOTARGET, v.8, no.45, pp.79414 - 79424 | - |
dc.relation.isPartOf | ONCOTARGET | - |
dc.citation.title | ONCOTARGET | - |
dc.citation.volume | 8 | - |
dc.citation.number | 45 | - |
dc.citation.startPage | 79414 | - |
dc.citation.endPage | 79424 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.subject.keywordPlus | AZACITIDINE TREATMENT FAILURE | - |
dc.subject.keywordPlus | LEUKEMIA GROUP-B | - |
dc.subject.keywordPlus | ELDERLY-PATIENTS | - |
dc.subject.keywordPlus | PHASE-III | - |
dc.subject.keywordPlus | LOW-RISK | - |
dc.subject.keywordPlus | DECITABINE | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | CARE | - |
dc.subject.keywordPlus | ORGANIZATION | - |
dc.subject.keywordAuthor | myelodysplastic syndrome | - |
dc.subject.keywordAuthor | discontinuation | - |
dc.subject.keywordAuthor | survival | - |
dc.subject.keywordAuthor | decitabine | - |
dc.subject.keywordAuthor | azacitidine | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.